Jubilant Pharmova Financial Statements

Jubilant Pharmova (JUBLPHARMA) reported revenue of ₹72.91B in FY2025 with net income of ₹8.36B. Total assets stood at ₹127.56B and free cash flow was -₹435.00M.

Jubilant Pharmova Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		61.16B	61.41B	63.20B	67.72B	72.91B
Cost of Rev. Cost of Revenue		-15.36B	-14.88B	-18.78B	-21.41B	-23.17B
Gross Profit		45.80B	46.53B	44.42B	46.31B	49.74B
SGA Sales, General & Admin		-31.66B	-34.86B	-36.28B	-36.61B	-37.44B
Op. Income Operating Income		10.65B	7.86B	2.61B	5.88B	8.62B
PBT Profit Before Tax		8.60B	6.30B	277.80M	1.71B	9.81B
Net Income		8.36B	4.13B	-648.80M	727.00M	8.36B
Dil. Shares Diluted Shares		159.27M	159.17M	159.15M	158.36M	158.42M
Diluted EPS		52.48	26.00	-3.83	4.86	52.85

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Jubilant Pharmova's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Jubilant Pharmova Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		29.53B	35.09B	37.62B	36.32B	35.10B
Non-curr. assets Total non-current assets		59.66B	64.82B	73.94B	79.16B	92.47B
Total assets		89.18B	99.90B	111.57B	115.49B	127.56B
Curr. liabilities Total current liabilities		10.49B	15.92B	17.72B	18.89B	21.65B
Non-curr. liab. Total non-current liabilities		31.28B	30.83B	39.92B	42.38B	43.53B
Total liabilities		41.77B	46.74B	57.65B	61.27B	65.18B
Total equity		47.42B	53.16B	53.92B	54.21B	62.39B
Total liab. & eq. Total liabilities & equity		89.18B	99.91B	111.57B	115.49B	127.56B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Jubilant Pharmova's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Jubilant Pharmova Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		8.71B	6.30B	277.80M	1.71B	9.81B
Operating CF Cash flow Operating Activities		17.84B	8.38B	6.61B	9.71B	10.72B
Capex Investments in PPE		-5.27B	-6.00B	-8.14B	-8.98B	-11.16B
Investing CF Cash flow Investing Activities		-7.39B	-3.80B	-5.44B	-6.08B	4.88B
Dividend Paid		-14.75M	-800.50M	-800.60M	-798.00M	-796.00M
Financing CF Cash flow Financing Activities		-17.09B	-326.00M	-1.57B	-4.33B	-14.53B
Cash (start) Cash at beginning of period		12.31B	5.02B	9.84B	10.14B	9.56B
Cash (end) Cash at end of period		5.02B	9.84B	10.14B	9.56B	10.88B
FCF Free Cash Flow		12.57B	2.38B	-1.54B	736.00M	-435.00M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Jubilant Pharmova's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025